This was based on the results of Study 42, evaluated olaparib in the dosage of 400 mg bid in heavily pretreated patients with recurrent, platinum resistant ovarian cancer, and a germline BRCA1/2 mutation, until disease progression or unacceptable toxicity [15]. This evidence concerns the gene BRCA1 and ovarian cancer.